BPC-157 Fact Sheet
| Molecular formula: | C62H98N16O22 |
| Molecular weight: |
1419.5 g/mol
|
| PubChem CID: | 108101 |
| Synonyms |
|
| Research Applications: |
|
BPC 157 Overview
BPC 157 is a peptide consisting of 15 amino acids, derived from a portion of body protection compound (BPC) that is produced in the human stomach. It is often referred to as a “healing peptide” due to its remarkable recovery and regenerative properties, particularly for the gastrointestinal tract and the musculoskeletal system.
BPC-157 and Wound Healing
BPC-157 has been found to have practical applicability in wound therapy, including incisional/excisional wounds, deep burns, diabetic ulcers, and alkali burns. It has been shown to promote healing by resolving vessel constriction, stabilizing the primary platelet plug, and resolving the clot. It has also been found to counteract bleeding disorders produced by amputation and/or anticoagulant application [R].
Research has shown that BPC-157 can induce nitric oxide generation, which is considered to play a significant role in tissue healing and angiogenesis. This nitric oxide modulation is involved in the healing effect of BPC-157 in different tissue injuries [R].
BPC-157 has also been found to interact with the nitric oxide system, providing endothelium protection and an angiogenic effect. It has been shown to stimulate the expression of the early growth response 1 gene, which is responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation [R].
BPC-157 and Gastrointestinal (GI) Health
BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice, and is effective across the entire gastrointestinal tract. It has been used in clinical trials for ulcerative colitis and multiple sclerosis, and has shown consistent healing effects on various wounds, including skin, muscle, tendon, ligament, bone, and ulcers in the entire gastrointestinal tract. BPC-157 has been effective in healing various types of fistulas, including external (esophagocutaneous, gastrocutaneous, duodenocutaneous, colocutaneous) and internal (colovesical, rectovaginal) fistulas [R].
Research has shown that BPC-157 may play a role in maintaining gastrointestinal mucosa integrity, acting as a novel cytoprotection mediator. It has been used in ulcerative colitis trials and has shown potential in counteracting the leaky gut syndrome and free radical scavenging activity in various tissues. It has also been found to counteract various encephalopathies and gastrointestinal and liver lesions induced by non-steroidal anti-inflammatory drugs (NSAIDs). In the context of the brain-gut and gut-brain axes, BPC-157 has demonstrated beneficial effects, including anxiolytic, anticonvulsive, and antidepressant effects [R, R].
BPC-157 has also shown potential in resolving major vessel occlusion disturbances, such as ischemia-reperfusion injury following the Pringle maneuver and Budd-Chiari syndrome. It has been suggested that BPC-157 may have a role in endothelium maintenance, which is crucial for the function of the gastrointestinal system [R].
BPC-157 and Neurological Health
BPC-157 has been shown to have beneficial effects on neurological disorders. It has been found to counteract various encephalopathies and behavioral disturbances, and it may also have a positive impact on muscle disabilities related to central nervous system disturbances. It has been suggested that BPC-157 therapy might recover many muscle disabilities, including those caused by traumatic brain injury, severe electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome, and NO-system blockade [R].